Fig. 4.

Association between baseline myeloid cell number and response to combo-immunotherapy. A Fresh tumor tissues and associated blood samples for each patient (n = 16) were stained and then analysed by flow cytometry. B The frequency of macrophages (CD14⁺ CD163⁺), mMDSC (CD14⁺ CD163⁻ HLA-DR^low), gMDSC (CD15⁺ CD14⁺) and granulocytes (CD15⁺) in tumor samples according to responder (R) or non-responder (NR) status is depicted. C Box plots showing PD-L1 expression on myeloid (CD11b⁺) and tumor cells. D Box plots showing PDL1 expression on different myeloid subtypes (macrophages (CD14⁺ CD163⁺), mMDSC (CD14⁺ CD163⁻ HLA-DR^low), gMDSC (CD15⁺ CD14⁺) and granulocytes (CD15⁺)) in tumor samples. E Box plots showing PDL1 expression on different myeloid subtypes (macrophages (CD14⁺ CD163⁺), mMDSC (CD14⁺ CD163⁻ HLA-DR^low), gMDSC (CD15⁺ CD14⁺) and granulocytes (CD15⁺)) in tumor samples according to responder (R) or non-responder (NR) status. Statistical difference was determined by a Mann–Whitney test. ns not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001